Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)Ethan Basch, Deborah Schrag, Bryce B. Reeve et al.|JNCI Journal of the National Cancer Institute|2014Cited by 1.1k
Validity and Reliability of the US National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)Amylou C. Dueck, Ethan Basch, Tito R. Mendoza et al.|JAMA Oncology|2015Cited by 1k
Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trialPaul D. Brown, John H. Suh, David Roberge et al.|Neuro-Oncology|2013Cited by 942
Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001Paul D. Brown, Vinai Gondi, Stephanie L. Pugh et al.|Journal of Clinical Oncology|2020Cited by 827
Management of Fatigue in Adult Survivors of Cancer: ASCO–Society for Integrative Oncology Guideline UpdateJulienne E. Bower, Karen M. Mustian, Christina Lacchetti et al.|Journal of Clinical Oncology|2024Cited by 210